TY  - GEN
AU  - Kulpeng,Wantanee
AU  - Sompitak,Sumalai
AU  - Jootar,Saengsuree
AU  - Chansung,Kanchana
AU  - Teerawattananon,Yot
TI  - Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand
SN  - 1879-114X
PY  - 2016///0115
KW  - Budgets
KW  - Cost-Benefit Analysis
KW  - Dasatinib
KW  - economics
KW  - Drug Costs
KW  - Humans
KW  - Imatinib Mesylate
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - drug therapy
KW  - Leukemia, Myeloid, Chronic-Phase
KW  - Markov Chains
KW  - Protein Kinase Inhibitors
KW  - Pyrimidines
KW  - Quality of Life
KW  - Quality-Adjusted Life Years
KW  - Thailand
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.clinthera.2014.02.008
ER  -